Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE

BACKGROUND: Bone remodeling is disrupted in metastatic disease, which affects > 70% of metastatic castration-resistant prostate cancer (mCRPC) patients. As a result, abnormal levels of specific bone turnover biomarkers (BTMs) are released. In this prospective ancillary analysis of the Italian rea...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Bone Oncol
Autors principals: Santini, Daniele, Cinieri, Saverio, Gasparro, Donatello, Bordonaro, Roberto, Guglielmini, Pamela Francesca, Chiuri, Vincenzo Emanuele, D'Angelillo, Rolando M, Ceresoli, Giovanni Luca, Fagnani, Daniele, Acquati, Mirko, Mencoboni, Manlio, Lanzetta, Gaetano, Sartori, Donata, Carlini, Paolo, Panebianco, Fabiana, Beccaglia, Patrizia, Procopio, Giuseppe
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779770/
https://ncbi.nlm.nih.gov/pubmed/33425672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jbo.2020.100341
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars